L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial - Nature Communications Recently, the dose escalation stage of the GLORIA trial investigating NOX-A12 (L-RNA aptamer-based CXCL12 inhibitor) in combination with radiotherapy in patients with glioblastoma was reported. Here, ...

Tumor revascularization in #glioblatoma is driven by 2 spatially distinct pathways. The GLORIA trial investigated a novel first-line approach for #glioblastoma patients with unfavorable prognostic features: #radiotherapy + #LRNAaptamer targeting #CXCL12 + #bevacizumab

www.nature.com/articles/s41...